ArticleThe American journal on addictions2025
Cannabis involvement in posttraumatic stress disorder emergency department visits after cannabis legalization.
Article in The American journal on addictions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cannabis involvement in posttraumatic stress disorder emergency department visits after cannabis legalization.The American journal on addictions · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND AND
objectivesIndividuals with posttraumatic stress disorder (PTSD) have an elevated risk of cannabis use disorder. However, the effect of cannabis legalization on use among individuals with PTSD is unclear. We evaluated changes in cannabis involvement in emergency department (ED) visits for PTSD after medical and nonmedical legalization in Ontario, Canada.
methodsThis repeated cross-sectional study used health administrative data to identify all ED visits for PTSD among Ontario residents aged 10-105 between 2008 and 2022 (n = 15.7 million). We identified PTSD ED visits with a co-diagnosis of cannabis (main exposure) or alcohol (control condition) and examined changes across four policy periods (medical legalization with restrictions, expanded medical legalization, nonmedical legalization with restrictions, and nonmedical commercial expansion) using Poisson models.
resultsAmong 381,450 PTSD ED visits, 4593 (1.29%) co-involved cannabis and 11,625 (3.05%) co-involved alcohol. Rates of cannabis involvement in PTSD ED visits increased by 151% (Incidence Rate Ratio [IRR]: 2.51; 95% CI: 2.24, 2.82) between the first and last policy periods (0.13 vs. 0.33 per 100,000 individuals), while alcohol-involvement increased by 58% (IRR: 1.58; 95% CI: 1.47, 1.68). Cannabis involvement in PTSD ED visits increased steadily over the study period, with no significant association between policy periods and this trend. DISCUSSION AND
conclusionsCannabis involvement in PTSD ED visits has increased over time during a period of liberalization of cannabis policy, but may be attributed to increased access and normalization rather than policy changes directly. SCIENTIFIC SIGNIFICANCE: Findings underscore the need for improved detection of and targeted interventions for disordered cannabis use among individuals with PTSD in regions with legalized cannabis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.